ARGX — argenx SE

Summary of ARGX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Product Net Sales: $1.3 billion, reflecting a 90% year-over-year growth.
• Full Year 2025 Product Net Sales: $4.2 billion, with a 68% increase in U.S. sales ($1.1 billion).
• Operating Expenses: $955 million in Q4, up $149 million from Q3; total operating expenses for the year were $2.7 billion.
• Operating Profit: $367 million for Q4 and $1.1 billion for the full year, marking the first year of annual operating profitability.
• Net Profit: $533 million for Q4 and $1.3 billion for the full year.
• Cash Position: $4.4 billion at the end of Q4, a $1 billion increase over the year.

2. Strategic Updates and Business Highlights

• VYVGART Growth: The product continues to lead in both Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with a successful launch of a prefilled syringe for self-injection.
• Phase III ADAPT OCULUS Study: Positive results for ocular MG, with plans to file a supplemental Biologics License Application (sBLA) with the FDA.
• Pipeline Expansion: Introduction of four new molecules and plans to advance two next-generation FcRn assets (ARGX-213 and ARGX-124).
• Market Positioning: VYVGART is the fastest-growing biologic in MG, with a focus on expanding into seronegative MG and ocular MG, targeting a total addressable population of approximately 60,000 patients in the U.S.

3. Forward Guidance and Outlook

• 2026 Expectations: Continued growth in operating expenses is anticipated, with a focus on R&D to support pipeline development. The effective tax rate is expected to remain in the low to mid-teens.
• Market Dynamics: The company expects to maintain strong growth in MG and CIDP, with ongoing efforts to expand patient access and prescriber adoption.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: There is emerging competition in the MG space, which could impact VYVGART's market share. However, management remains confident in VYVGART's profile and its established leadership position.
• Operational Challenges: Seasonal dynamics, such as reverifications and winter storms, may affect Q1 performance, similar to previous years.

5. Notable Q&A Insights

• Market Research: The company has conducted extensive market research to assess the addressable market for ocular and seronegative MG, with expectations of a similar pricing strategy to existing MG treatments.
• CIDP Growth: The company is beginning to see expansion beyond the initial 12,000 CIDP patients, with a focus on increasing prescriber adoption and patient activation.
• Regulatory Strategy: For the Graves disease program, the FDA has requested two trials, which the company is executing.
• Long-term Data Collection: There are plans to collect long-term data on ocular MG to assess the potential for delaying progression to generalized MG.

Overall, ARGX reported strong financial performance and strategic progress in its pipeline, while also acknowledging competitive challenges and operational dynamics that could impact future growth.